| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21011 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. |
| Assessment Process | |
| Rapid review commissioned | 24/03/2021 |
| Rapid review completed | 28/04/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/05/2021 |
| Pre-submission consultation with Applicant | 04/10/2021 |
| Full submission received from Applicant | 07/02/2022 |
| Preliminary review sent to Applicant | 02/09/2022 |
| NCPE assessment re-commenced | 11/11/2022 |
| Factual accuracy sent to Applicant | 12/01/2023 |
| NCPE assessment re-commenced | 20/01/2023 |
| NCPE assessment completed | 27/01/2023 |
| NCPE assessment outcome | The NCPE recommends that olaparib in combination with bevacizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. September 2023
